Factors Influencing Mortality in Acromegaly

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 2, 2004, Pages 667-674

  Holdaway, Ian M ^a   Rajasoorya, Raja C ^c   Gamble, Greg D ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c ALEXANDRA HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN;

ACROMEGALY; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR; SURGICAL MORTALITY;

ACROMEGALY; ADULT; AGED; AGING; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; TIME FACTORS;

EID: 1442303361     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031199     Document Type: Article

References (31)

1. Nabarro JDN 1987 Acromegaly. Clin Endocrinol (Oxf) 26:481-512
2. Wass JAH, Thorner MO, Morris DV, Rees LH, Stuart Mason A, Jones AE, Besser GM 1977 Long-term treatment of acromegaly with bromocriptine. Br Med J 1:875-878
3. Lieberman SA, Hoffman AR 1990 Sequelae to acromegaly: reversibility with treatment of the primary disease. Horm Metab Res 22:313-318
4. Holdaway IM, Rajasoorya C, Wong J, Orr-Walker B, Gamble G 1998 The natural history of functional pituitary adenomas. In: Webb SM, ed. Pituitary tumours: epidemiology, pathogenesis and management. Bristol: BioScientifca; 31-42
5. Holdaway IM, Rajasoorya C 1998 Epidemiology of acromegaly. Pituitary 2:29-41
6. Wright AD, Hill DM, Lowy C, Fraser TR 1970 Mortality in acromegaly. Q J Med 34:1-16
7. Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R 1980 Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12:71-79
8. Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B 1988 Epidemiology and long term survival in acromegaly. Acta Med Scand 223:327-335
9. Ritchie CM, Atkinson AB, Kennedy AL, Lyons AR, Gordon DS, Fannin T, Hadden DR 1990 Ascertainment and natural history of treated acromegaly in Northern Island. Ulster Med J 59:55-62
10. Bates AS, Van't Hoff W, Jones JM, Clayton RN, 1993 An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
11. Etxabe J, Gaztambide S, Latorre P, Vazquez JA 1993 Acromegaly: an epidemiological study. J Endocrinol Invest 16:181-187
12. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95-102
13. Orme SM, McNally RJQ, Cartwright RA, Belchetz PE 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. J Clin Endocrinol Metab 83:2730-2734
14. Shimatsu A, Yokogoshi Y, Saito S, Shimizu N, Irie M 1998 Long-term survival and cardiovascular complications in patients with acromegaly and pituitary gigantism. J Endocrinol Invest 21:55-57
15. Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB 1998 Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 83:3411-3418
16. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419-3426
17. Beauregard C, Truong U, Hardy J, Serri O 2003 Long-term outcome and mortality after transsphenoidal adenectomy for acromegaly. Clin Endocrinol (Oxf) 58:86-91
18. Ho KKY, Weissberger AJ 1994 Characterization of 24-hour growth hormone with secretion in acromegaly; implications for diagnosis and therapy. Clin Endocrinol (Oxf) 41:75-83
19. Gluckman PD, Johnson-Barrett J, Butler JH, Edgar B, Gunn TR 1983 Studies on insulin-like growth factor-1 and II by specific radioligand assays in umbilical cord blood. Clin Endocrinol (Oxf) 19:405-413
20. Holdaway IM, Mason BH, Lethaby AE, Singh V, Harman JE, MacCormick M, Civil ID 1999 Serum levels of insulin-like growth factor binding protein-3 in benign and malignant breast disease. Aust NZ J Surg 69:495-500
21. Wrightson P, Rajasoorya C, Holdaway IM, Scott DJ 1994 Acromegaly: factors affecting the long-term outcome after surgical treatment. J Clin Neurosci 1:164-172
22. Melmed S, Jackson I, Kleinberg D, Klibanski A 1998 Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646-2652
23. Barkan AL, Beitins IZ, Kelch RP 1998 Plasma insulin-like growth factor-I/somatomedin-C in acromegaly: correlation with the degree of growth hormone hypersecretion. J Clin Endocrinol Metab 67:69-73
24. Rosen T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
25. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. Lancet 357:425-431
26. Bulow B, Hagmar L, Mioczy Z, Nordstrom CH, Erfurth EM 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 46:75-81
27. Brabant G 2003 Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. Eur J Endocrinol 148:S15-S20
28. Brada M, Burchell L, Ashley S, Traish D 1999 The incidence of cerebrovascular accidents in patients with pituitary adenoma. Int J Radiat Oncol Biol Physiol 45:693-698
29. Erfurth EM, Bulow B, Svahn-Tapper G, Norrving B, Odh K, Mikoczy Z, Bjork J, Hagmar L 2002 Risk factors for cerebrovascular deaths in patients operated and irradiated for pituitary tumors. J Clin Endocrinol Metab 87:4892-4899
30. Kaltsas GA, Isidori AM, Florakis D, Trainer PJ, Camacho-Hubner C, Afshar F, Sabin I, Jenkins JP, Chew SL, Monson JP, Besser GM, Grossman AB 2001 Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity. J Clin Endocrinol Metab 86:1645-1652
31. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342:1171-1177